Targeted antibody ventures Mersana and CytomX attract venture dollars amid partnering promise
This article was originally published in Scrip
Executive Summary
Companies on opposite US coasts announced venture capital funding on 31 July to boost next-generation targeted discovery and development platforms. Cambridge, Massachusetts-based antibody-drug conjugate (ADC) specialist Mersana Therapeutics raised $27 million in a Series A-1 round and CytomX Therapeutics in San Francisco increased its Series B round to $41 million for its tissue-specific antibodies.